Last reviewed · How we verify
Staphylococcal investigational vaccine GSK2392106A — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Staphylococcal investigational vaccine GSK2392106A (Staphylococcal investigational vaccine GSK2392106A) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Staphylococcal investigational vaccine GSK2392106A TARGET | Staphylococcal investigational vaccine GSK2392106A | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Staphylococcal investigational vaccine GSK2392106A CI watch — RSS
- Staphylococcal investigational vaccine GSK2392106A CI watch — Atom
- Staphylococcal investigational vaccine GSK2392106A CI watch — JSON
- Staphylococcal investigational vaccine GSK2392106A alone — RSS
Cite this brief
Drug Landscape (2026). Staphylococcal investigational vaccine GSK2392106A — Competitive Intelligence Brief. https://druglandscape.com/ci/staphylococcal-investigational-vaccine-gsk2392106a. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab